August 16, 2012

Abbott Announces Extension of Global Agreement with Insulet


Integration of Abbott Glucose Technology with Insulet Insulin Pump to Continue

Abbott's FreeStyle blood glucose monitoring technology1 will continue to be integrated with Insulet's current and future versions of the OmniPod Personal Diabetes Manager (PDM). This follows Abbott's announcement today that it has extended its existing agreement with Insulet on a non-exclusive basis through 2014.

"We've had a strong relationship with Insulet since 2002 and are pleased to extend our agreement," said Heather Mason, senior vice president, Abbott Diabetes Care. "This will be welcome news to patients who rely on having the accuracy of our FreeStyle technology combined with their OmniPod System, allowing them to continue testing their blood glucose without interruption."

The FreeStyle blood glucose meter is built into the Insulet handheld PDM (PDM UST200). This enables users to test without having to carry a separate meter or transfer blood glucose results between devices.

FreeStyle Test Strips feature patented ZipWik tabs, designed to ensure fast blood application and fewer wasted test strips.2

About Abbott Diabetes Care
Abbott Diabetes Care, based in Alameda, California, is a leader in developing, manufacturing and marketing glucose monitoring systems designed to help people better manage their diabetes. Additional information about Abbott Diabetes Care may be found at www.abbottdiabetescare.com.

About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.

Abbott's information and news releases are available on the company's Web site at www.abbott.com.

 

Media:
Jeff Christensen (510) 749-6307 Financial:
Tina Ventura (847) 935-9390

 

April 10, 2012

Important Medical Device Notification: Updated Ranges for FreeStyle Control Solution


Updated Ranges for FreeStyle Control Solution Used with FreeStyle, FreeStyle Lite, and FreeStyle InsuLinx Blood Glucose Test Strips

 

 

Dear Valued Customer,

Recently, Abbott Diabetes Care has determined, as part of our continuous manufacturing process monitoring, that the FreeStyle Control Solution ranges found on the FreeStyle test strip vial label as well as the FreeStyle test strip insert require an update. This notification only applies to FreeStyle brand test strips that have a butterfly and tapered end with “fill assist tabs” (refer to image below).

This change in control solution ranges does not affect blood glucose test results, and it does not affect any other Abbott Diabetes Care products. You may continue to test your blood glucose as directed by your health care provider with FreeStyle products.

Control solution is used to check the performance of the meters, test strips and your testing technique. Refer to your test strip insert or the user manual provided in your blood glucose monitoring system kit for instructions on testing with control solutions. Please note that all other information in the test strip insert is current and should continue to be followed.

What You Need to Do

If your test strip lot number is lower than 1258621:

Apply the control solution ranges as shown in Table 1. Your test strip vial label may have only the "Normal" range, "Low" and "High" ranges or all three ranges.

If your test strip lot number is 1258621 or higher:

Apply the control solution ranges as shown in Table 2. Please note, your vial label may already reflect the ranges in Table 2.

 

If you have any further questions, please call Abbott Diabetes Care Customer Care at 1-800-359-2391.

We thank you for your continued support of Abbott Diabetes Care and FreeStyle products.  

 

 

Media:
Ann Smith (847) 937-6123

 

 

March 8, 2012

FreeStyle InsuLinx Blood Glucose Monitoring System Receives FDA Clearance


Abbott's New FreeStyle InsuLinx Blood Glucose Monitoring System Receives FDA Clearance

 

  • The Newest Meter in Abbott’s Portfolio of Products Features Automated Logbook, Touch Screen Interface and USB Connectivity for Plug-and-Play Reports

 

Abbott (NYSE: ABT) today announced that it has received U.S. Food and Drug Administration (FDA) clearance for the FreeStyle InsuLinx Blood Glucose Monitoring System, the first from Abbott to include a touch-screen interface, automated logbook and several personalization features designed to improve the diabetes management experience for patients. This unique device is also equipped with built-in FreeStyle Auto-Assist software that enables patients to track progress, analyze trends and easily display data for their health care providers. The FreeStyle InsuLinx System will be available to U.S. consumers within the coming months.

According to the American Diabetes Association (ADA), approximately 25.8 million people in the United States have diabetes1, and of those, many require insulin to manage their condition. The FreeStyle InsuLinx System is the newest addition to Abbott’s portfolio of glucose monitoring systems and is designed to use FreeStyle technology to help insulin-using patients monitor their blood glucose levels to allow them to more effectively manage their condition. Specifically, the FreeStyle InsuLinx System offers:

  • Touch screen designed for ease of use
  • Automated logbook that assists with tracking logged insulin doses and blood glucose levels
  • Personalization features, including the ability to upload weekly messages, pre- and post-meal markers and a personal photograph to the home screen
  • FreeStyle Auto-Assist software that can be uploaded to a computer via USB connectivity and is designed to help people with diabetes, health care teams and caregivers manage diabetes with reports, reminders and messages

 

The new FreeStyle InsuLinx blood glucose monitor includes an automated logbook, easy-to-use touch screen and personalization features.

The FreeStyle InsuLinx System is compatible with the FreeStyle InsuLinx blood glucose test strips.

"The new FreeStyle InsuLinx System represents Abbott's latest advancement in delivering innovative products for people with diabetes who use insulin," said Heather L. Mason, senior vice president, Abbott Diabetes Care. "The improved functionality, data sharing tools and personalization features are designed to improve the diabetes management experience for patients. We are excited to make this product available to diabetes patients in the United States."

About Abbott Diabetes Care
Abbott Diabetes Care, based in Alameda, California, is a leader in developing, manufacturing and marketing glucose monitoring systems designed to help people better manage their diabetes. Additional information about Abbott Diabetes Care may be found at www.abbottdiabetescare.com.

About Abbott
Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.

 

 

Media:
Ann Smith (847) 937-6123

 

 

Financial:
Tina Ventura (847) 935-9390



ADC-01541 Ver 1.0 06/15

You are about to leave for a 3rd party website

The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.

Do you wish to leave this site?

 


Coming soon...